San Diego, CA, USA – December 18, 2014 – HUYA Bioscience International, a leader in accelerating the global development of China’s pharmaceutical innovations, today announced a strategic collaboration agreement with China Wuqing Development Area, a state-level economic and technological development area located between Beijing and Tianjin. The collaboration will focus on promoting biomedical innovations from companies located in the Area.
HUYA is one of the first companies to have recognized China’s potential for helping to meet the global need for new preclinical and clinical stage compounds. The company is focused on speeding the development and value creation for China-sourced novel biopharmaceutical compounds in worldwide markets. HUYA has established a series of collaborations with leading universities and research institutes throughout China and has pioneered in-licensing of both preclinical and clinical stage compounds from the country.
China Wuqing Development Area is a national level economic-technological development zone and a high technology industrial park approved by China’s State Council. Situated between the downtown areas of Beijing and Tianjin, two of China’s four municipalities directly under the central government, the Area has attracted over 1400 enterprises from more than 50 countries and amassed investments totaling 120 billion RMB (19.5 billion USD). Biomedicine is a leading industry in the Area and a focus of its two new sections–the EU-Industry Park and the Jingjin Gaocun Science and Technology Innovation Park.
The alliance combines the expertise of both HUYA and China Wuqing Development Area to promote biomedical innovations originating in Wuqing with global market potential. Chinese pharmaceutical companies in the Area will be able to leverage HUYA’s international pharmaceutical knowledge and networks, and consult with HUYA’s team of experts in drug development and commercialization. HUYA will have the right of priority review to evaluate certain research and development projects of these companies and provide advice and consultation as needed. HUYA will also assist the Park in introducing business and investment opportunities.
“This is an exciting start of HUYA’s collaboration with prestigious China Wuqing Development Area to accelerate the development and globalization of innovative biomedical products from Wuqing,” said Clement Gingras, HUYA’s Chief Technology Officer and Chief Operating Officer Asia. “With both sides’ complementing strengths, this partnership will bring value to both parties as well as other organizations in the Area.”
Jibin Wang, Deputy General Manager of the Wuqing Development Area General Corporation, the management entity of the Area, was also very upbeat about the alliance. “Our unique advantages of location and abundant resources for the biomedical industry will create synergies with HUYA’s international insight and expertise in innovative drug development,” he said. “We look forward to productive collaboration over the coming years.”
About HUYA Bioscience International
HUYA Bioscience International is a leader in enabling and accelerating the global development of novel biopharmaceutical product opportunities originating in China. HUYA has established extensive collaborations with Chinese biopharmaceutical academic and commercial organizations to speed development and value creation in worldwide markets for China-sourced product candidates. With the largest Chinese compound portfolio covering all therapeutic areas, HUYA has emerged as the partner-of-choice for building and maximizing the value for biopharmaceutical innovation in China. HUYA has offices in the US, the UK, and Japan, and in eight strategic locations across China, with joint headquarters in San Diego and Shanghai. HUYA’s team is practiced in leading pharmaceuticals and medical devices through FDA and PMDA submission and approval to commercialization. www.huyabio.com
About China Wuqing Development Area
China Wuqing Development Area, approved by the State Council in 1991, is both a state-level economic and technological development area and a state-level hi-tech industrial park with a total 93 km2 planned area. It is located in the Wuqing District of Tianjin near Beijing, thus known as the “corridor of Beijing and Tianjin.” With 1.1 million residents and 1574 km2 area, Wuqing is one of the fastest growing regions in terms of economic development in Tianjin. Besides its favorable location with convenient transportation links, the Area’s advantages also include abundant human resources, highly efficient supporting facilities and administrative services, and preferential policies for investment projects. In addition to biomedicine, the other five leading industries are electronic information, new material, machinery manufacturing, automobile and spare parts, and new energy. http://en.tjuda.com/
Clement Gingras CTO and COO Asia
HUYA Bioscience International
Yung-Chih Wang, PhD, MBA
VP, Corporate Development China HUYA Bioscience International